LLY

Eli Lilly & Co

Approval Confirmed

Foundayo

adults with obesity, or overweight with weight-related medical problems

117d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

LLY

Eli Lilly & Co

Phase 3 Confirmed

Foundayo

adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk

117d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

LLY

Eli Lilly & Co

Phase 3 Confirmed

Jaypirca

relapsed or refractory CLL or SLL

117d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

LLY

Eli Lilly & Co

Phase 3 Confirmed

Taltz and Zepbound

adults with psoriasis and obesity or overweight

117d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

LLY

Eli Lilly & Co

Phase 3 Confirmed

retatrutide

type 2 diabetes

117d ago Apr 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

LLY

Eli Lilly and Company

Phase 3 Estimated

Tirzepatide

Type 1 Diabetes

T-minus 97 days ~ Nov 30, 2026

ClinicalTrials.gov verified 2mo ago

Countdown card →

LLY

Eli Lilly and Company

Phase 2 Estimated

Brenipatide

Smoking

T-minus 187 days ~ Feb 28, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →